메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Visionary Holdings (Nasdaq: GV) Secures Global License for Breakthrough Stem Cell Technology Aimed at Diabetes Remission and Potential Complete Cure in a USD 150 Billion Global Market

TORONTO, Oct. 13, 2025 -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary, Visionary Holdings (Asia) Limited, has entered into a Global Product and Technology Licensing Agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. ("Yike"). The agreement grants GV the worldwide rights to apply Yike's breakthrough stem cell technology, which has demonstrated significant potential in advancing treatments for diabetes and with other regenerativ
- 김갑성 기자
- 2025-10-13 21:40
Complete Genomics announces Gene by Gene as its newest sequencing service provider at ASHG

BOSTON, Oct. 13, 2025 -- Complete Genomics, a leading innovator in genomic sequencing, today announced at the American Society of Human Genetics Annual Meeting that it has added Houston-based Gene by Gene, a leading genetics laboratory, to its Sequencing Service Provider Program. The Complete Genomics Service Provider Program connects its customers to a network of service providers, offering access to high-quality sequencing services using Complete Genomics DNBSEQ™ sequencing platforms. "We're excited about partnering with Complete Genomics, which we believe will contribut
- 김갑성 기자
- 2025-10-13 21:00
NEXTBIOMEDICAL Announces First Patient Enrolled in U.S. FDA Pivotal Trial of Nexsphere-F™ for Knee Osteoarthritis Pain

RESORB Study Marks Major Step Toward U.S. Regulatory Approval and Global Commercialization SEOUL, South Korea, Oct. 13, 2025 -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, today announced the enrollment of the first patient in its U.S. pivotal clinical trial evaluating Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization. This milestone represents a significant advancement in NEXTBIOMEDICAL's U.S. regulatory pathway, following FDA approval of its Investigational Device
- 김갑성 기자
- 2025-10-13 21:00
iRegene Therapeutics announced promising NouvNeu001 Phase I clinical data

CHENGDU, China, Oct. 13, 2025 -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company") is recognized as a biotechnology company pioneering chemically induced allogeneic cell therapy. iRegene's lead product, NouvNeu001, is the 1st iPSC therapy to receive IND approval from both the NMPA and the FDA to treat Parkinson's disease (PD). Recently, NouvNeu001 Phase I clinical data were presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS). Excellent safety and tolerability were observed for up to 15 months post-transplantation, no
- 김갑성 기자
- 2025-10-13 21:00
Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics

Headlines: Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1 Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample.2 Decreases sample volumes by 100 times vs. current methods for assessing cells and nucleic acids.3 MILFORD, Mass., Oct. 13, 2025 -- Waters Corporation (NYSE: WAT) today unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS)
- 김갑성 기자
- 2025-10-13 20:36
Thousand Oaks Biologics Shanghai ADC Site receives EU QP Declaration

SHANGHAI, Oct. 13, 2025 -- Thousand Oaks Biologics' antibody-drug conjugate (ADC) manufacturing site successfully passed an audit conducted by a European Union Qualified Person (QP) and formally received a QP Declaration. This milestone certifies that the company's quality management system and commercial production capability in the field of antibody-drug conjugates (ADCs) comply with EU Good Manufacturing Practice (GMP) standards, positioning Thousand Oaks Biologics Shanghai as one of the few CDMOs in China offering end-to-end international ADC services. The five-day on-site audit to
- 김갑성 기자
- 2025-10-13 20:00
Chiron Medical Launches "Early Check, Early Hope" Campaign, Embracing Pink for Breast Cancer Awareness

HONG KONG, Oct. 13, 2025 -- According to government statistics[1], breast cancer ranks as the third leading cause of cancer deaths among women in Hong Kong, with an average of one in every 14 women likely to be diagnosed with the disease in their lifetime. The medical community widely believes that early detection significantly increases the success rate of treatment, making regular screenings and disease awareness essential. In celebration of Pink Day and International Breast Cancer Awareness Month, Chiron Medical invites all sectors to participate in launching "Early Check, Early Hope,
- 김갑성 기자
- 2025-10-13 19:46
LTS expands its CDMO capabilities with the acquisition of Renaissance Lakewood

ANDERNACH, Germany, Oct. 13, 2025 -- LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company today announces the acquisition of Renaissance Lakewood, LLC ("Renaissance"), a US-based contract development and manufacturing organization (CDMO) specializing in nasal sprays and sterile dosage forms. With the acquisition, Renaissance facilities will become part of the worldwide operations network of LTS, along with LTS' existing facilities in Andernach, Germany, West Caldwell, NJ, US, St. Paul, MN, US and Netanya, Israel. The acquisitio
- 김갑성 기자
- 2025-10-13 18:00
ReviR Therapeutics Receives Orphan Drug Designation from FDA for RTX-117 to Treat Charcot-Marie-Tooth Disease

BRISBANE, Calif. , Oct. 13, 2025 -- ReviR Therapeutics, a biotech company focused on developing novel treatments for neurogenetic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for RTX-117, its lead investigational therapy for Charcot-Marie-Tooth disease (CMT). ReviR is preparing to launch a Phase 1 clinical trial in healthy volunteers in early 2026 to evaluate the safety, tolerability, and pharmacokinetics of RTX-117, with a Phase Ib/IIa study in CMT patients planned to follow. CMT is the most prevalent inherited p
- 김갑성 기자
- 2025-10-13 18:00
AnnJi Showcases Clinical Breakthrough of AJ201 at WMS 2025

TAIPEI, Oct. 13, 2025 -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) announced that the Phase 2a clinical result of AJ201 for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease) was selected as one of the seven Late-Breaking Abstracts at the World Muscle Society (WMS) 2025 International Congress in Vienna. Dr. Tahseen Mozaffar, an investigator of the study, presented the study outcome, emphasizing the therapeutic potential of AJ201 for SBMA patients. AJ201, an oral suspension of a novel curcumin analog-Rosolutamide, offers ease of use for patients with s
- 김갑성 기자
- 2025-10-13 16:03

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-11-04_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 04일 19시 40분